This page shows the latest PD-L1/ PD-1 inhibitor news and features for those working in and with pharma, biotech and healthcare.
Bintrafusp alfa is part of a new wave of bispecific antibodies that are currently being developed by a number of companies as potential successors to the PD-1/PD-L1 inhibitor ... class. The molecule is designed to simultaneously target two
PD-L1 inhibitor failed to improved progression-free survival. Roche’s Genentech division has reported that Tecentriq, plus Avastin, was unable to improve progression-free survival as a front-line treatment ... The FDA approval for Imfinzi makes AZ’s
The green light makes Imfinzi (durvalumab) the first PD-1/PD-L1 inhibitor to challenge Roche’s Tecentriq (atezolizumab) in ES-SCLC, which became the first checkpoint inhibitor to be approved ... In ES-SCLC, additional heavyweight competition could be
The approval in oesophageal cancer is particularly important for BMS as it continues to fight for its place in the PD-1/L1 inhibitor class, while Merck &Co’s Keytruda (pembrolizumab) ... The MHLW approved Opdivo based on the results from the phase 3
Tecentriq also beat chemotherapy in terms of patients who experienced grade 3-4 treatment-related adverse events, with 12.9% of people treated with the PD-L1 inhibitor experiencing one compared ... However, the NSCLC therapy area is dominated by
Data demonstrated a delay in disease progression or death. Merck &Co/MSD has chalked up a clinical trial win for its PD-1 inhibitor Keytruda in triple-negative breast cancer that ... Keytruda is the top-selling PD-1/PD-L1 inhibitor worldwide thanks to
More from news
Approximately 1 fully matching, plus 59 partially matching documents found.
cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing fast.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Innovative Trials is a leading global clinical trial patient recruitment company. With over 10 years’ experience, Innovative Trials deploys “boots-on-the-ground”...